India's Sun Pharma posts lower quarterly profit on one-time acquisition-related charge
India's Sun Pharma posts lower quarterly profit on one-time acquisition-related charge Oct 30 (Reuters) - India's Sun Pharmaceutical Industries SUN.NS reported a drop in second-quarter profit on Friday, dragged by a one-time charge related to its acquisition of Organon.
Consolidated net profit fell to 19.89 billion rupees ($209.31 million) in the quarter ended September 30 from 31.18 billion rupees a year earlier.
The drugmaker booked a one-time charge of 12.69 billion rupees, largely comprising acquisition-related costs for its planned purchase of Organon, along with provisions linked to India's new labour code framework.
($1 = 95.0250 Indian rupees)
(Reporting by Kashish Tandon in Bengaluru; Editing by Jochelle Mendonca)
((Kashish.Tandon@thomsonreuters.com; 8800437922;))
Recent news on Sun Pharmaceutical Industries
See all newsROI-US blue wave reshapes Asia's winners and losers: Manishi Raychaudhuri
Brief: Sun Pharma Clarifies Regarding News Report Relating To Company's Assam Facility
Street View: India's Sun Pharma Organon buy, psoriasis drug are risk factors
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses